telbivudine or lamivudine — Competitive Intelligence Brief

telbivudine or lamivudine (telbivudine or lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor. Area: Infectious Disease.

phase 3 Nucleoside reverse transcriptase inhibitor Hepatitis B virus DNA polymerase Infectious Disease Small molecule

Target snapshot

telbivudine or lamivudine (telbivudine or lamivudine) — Novartis. Telbivudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of viral DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
telbivudine or lamivudine TARGET	telbivudine or lamivudine	Novartis	phase 3	Nucleoside reverse transcriptase inhibitor	Hepatitis B virus DNA polymerase
Telbivudine, Adefovir dipivoxil	Telbivudine, Adefovir dipivoxil	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus DNA polymerase / reverse transcriptase
Adefovir (ADV)	Adefovir (ADV)	Bristol-Myers Squibb	phase 3	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus DNA polymerase / reverse transcriptase
lamivudine or entecavir	lamivudine or entecavir	Sun Yat-sen University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI)	Hepatitis B virus reverse transcriptase; HIV reverse transcriptase
ZIAGEN®	ZIAGEN®	ViiV Healthcare	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
DTG/ABC/3TC	DTG/ABC/3TC	Harvard School of Public Health (HSPH)	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
entecavir, lamivudine	entecavir, lamivudine	Asan Medical Center	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
2. Novartis · 1 drug in this class
3. University of Guadalajara · 1 drug in this class